Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in EGFR-Mutant NSCLC

This phase 2 multicenter randomized clinical trial including 88 patients compares progression-free survival, and secondarily overall survival, overall response rate, and adverse events, in patients with stage 4 EGFR-mutant non–small cell lung cancer treated with erlotinib plus bevacizumab vs…

Read the full article here

Related Articles